Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study Cohort 2 included 38 patients (61% male; median age 72.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results